血清CEA、CA19-9联合CRP在消化道恶性肿瘤的诊断价值分析

摘要 目的：探讨与分析血清CEA、CA19-9联合CRP在消化道恶性肿瘤的诊断价值。方法：2019年8月到2022年5月选择在本院诊治的消化道恶性肿瘤患者150例作为消化道恶性肿瘤组，同期选择在本院体检的健康人群150例作为健康组。采集两组人群的血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）、C-反应蛋白（CRP）含量，调查患者的病理特征并判断诊断价值。结果：消化道恶性肿瘤组的血清CEA、CA19-9、CRP含量都高于健康组（P<0.05）。消化道恶性肿瘤组的CEA、CA19-9、CRP阳性率为54.7 %、58.7 %、60.7 %，高于健康组的3.3 %、4.0 %、4.7 %（P<0.05）。在消化道恶性肿瘤组中，不同组织学分化、临床分期、淋巴结转移患者的血清CEA、CA19-9、CRP含量对比有差异（P<0.05）。血清CEA、CA19-9联合CRP诊断为阳性113例，在健康组中诊断为阳性3例，血清CEA、CA19-9联合CRP在消化道恶性肿瘤的诊断敏感性与特异性分别为75.3 %（113/150）和98.0 %（147/150）。结论：消化道恶性肿瘤患者多伴随有血清CEA、CA19-9、CRP的高表达，病理特征与血清CEA、CA19-9、CRP含量存在相关性，血清CEA、CA19-9联合CRP在消化道恶性肿瘤的诊断敏感性与特异性都比较好。

Analysis of The Diagnostic Values of Serum CEA, CA19-9 Combined with CRP in Digestive Tract Malignant Tumors

ABSTRACT Objective: To explore and analysis the diagnostic value of serum CEA, CA19-9 combined with CRP in digestive tract malignant tumors. Methods: From August 2019 to May 2022, 150 cases of patients with gastrointestinal malignant tumors diagnosed and treated in our hospital were selected as the gastrointestinal malignant tumor group, and 150 cases of healthy people who received physical examination in our hospital during the same period were selected as the healthy group. The serum carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and C-reactive protein (CRP) contents of the two groups of cases were collected, and the patients'' pathological features were investigated and determined the diagnostic values. Results: The levels of serum CEA, CA19-9 and CRP in digestive tract malignant tumor group were higher than those in healthy group (P<0.05). The positive rates of CEA, CA19-9 and CRP in the digestive tract malignant tumor group were 54.7 %, 58.7 % and 60.7 %, which were higher than those in the healthy group (3.3 %, 4.0 % and 4.7 %) (P<0.05). In the digestive tract malignant tumor group, there were significant differences in serum CEA, CA19-9 and CRP levels in patients with different histological differentiation, clinical stages and lymph node metastasis (P<0.05). The serum CEA, CA19-9 combined with CRP were diagnosed as positive in 113 cases, and 3 cases were diagnosed as positive in the healthy group. The diagnostic sensitivity and specificity of serum CEA, CA19-9 combined with CRP in digestive tract malignant tumors were 75.3 % (113/150) and 98.0 % (147/150), respectively. Conclusion: Patients with malignant tumors of the digestive tract are often accompanied by high expression of serum CEA, CA19-9 and CRP, and the pathological characteristics are correlated with the contents of serum CEA, CA19-9 and CRP. The sensitivity and specificity of serum CEA, CA19-9 combined with CRP in the diagnosis of digestive tract malignant tumors are relatively good.